Mesenchymal stem cells as a potential therapy for COVID-19.
Stem Cell Res Ther
; 11(1): 169, 2020 05 04.
Article
in English
| MEDLINE | ID: covidwho-165146
ABSTRACT
The outbreak of 2019 novel coronavirus disease (COVID-19) worldwide is becoming rapidly a major concern. The number of severe cases has increased dramatically worldwide, while specific treatment options are scarce. The main pathologic features of severe or critical COVID-19 were consistent with acute lung injure (ALI)/acute respiratory distress syndrome (ARDS), characterized by cellular fibromyxoid exudates, extensive pulmonary inflammation, pulmonary edema, and hyaline membrane formation. Mesenchymal stem cells (MSCs) can balance the inflammatory response and has been mentioned to be effective on ALI/ARDS from both infectious and noninfectious causes previously, presenting an important opportunity to be applied to COVID-19. In this commentary, we summarize the clinical trials of MSCs treatments on ALI/ARDS and raise MSCs as a hopefully alternative therapy for severe or critical COVID-19.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Coronavirus Infections
/
Mesenchymal Stem Cell Transplantation
Type of study:
Prognostic study
/
Randomized controlled trials
Topics:
Traditional medicine
Limits:
Animals
/
Humans
Language:
English
Journal:
Stem Cell Res Ther
Year:
2020
Document Type:
Article
Affiliation country:
S13287-020-01678-8
Similar
MEDLINE
...
LILACS
LIS